Recent advances in ICIs, particularly those targeting the PD-1/PD-L1 axis, have shown potential in improving clinical outcomes for CCA patients, although their effectiveness as monotherapies is limited by a suppressive immune microenvironment [53]. The gene discussed is CD274; the disease is cholangiocarcinoma.